Learn more about Peter Attia’s digital program
“Biological” clocks: a peek into the future or a haphazard guess of mortality?
Potential uses for the epigenetics of aging and why I don’t put much stock in epigenetics-based aging clocks at present
#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
#222 ‒ How nutrition impacts longevity | Matt Kaeberlein, Ph.D.
“It’s really important that we be willing to change our beliefs about nutrition and other aspects of health as more data comes in.” —Matt Kaeberlein
How long can we live?; suggested listening
Revisiting the podcast archive
Rapamycin: one of my favorite stories; Ryan Lochte’s flip side on missing Olympic redemption
A few things worth checking out: 07-18-2021
#123 – Joan Mannick, M.D. & Nir Barzilai, M.D.: Rapamycin and metformin—longevity, immune enhancement, and COVID-19
“I think what the mTOR inhibitors are doing is not stopping people from getting infected [with a virus], but if you get infected, there’s a better immune response and your symptoms will be milder.” — Joan Mannick